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On April 2006, the International Symposium
‘Pharmacovigilance of Herbal Medicines. Current Status
and Future Directions’, was held in London, organized by
the Royal Pharmaceutical Society of Great Britain
(RPSGB) in conjunction with the most important interna-
tional societies involved in the field. The Chairperson of the
Congress was Prof. Joanna Barnes of the School of
Pharmacy of the University of Auckland, NZ.
Major topics of the conference were: evaluation of
main concerns about correct reports of adverse reactions
to herbal extracts and possible future directions in
organizing an international and affordable signaling
system and to build a definitive international network
on the WHO database.
Compelling problems are due to the wide differences
that exist all over the world in nomenclature, adminis-
tration, extraction and use of medicinal herbs.
In addition, the clinical purposes for administration of
the same medicinal herbs often differ greatly among
traditional therapeutic systems according to the diagnosis
of the same diseases and in the recognition of energetic-
magical properties of some natural substances.
The congress has highlighted the necessity of a common
language not only for the botanical name of the plants
but also for the type of extraction, the clinical purpose
for the administration of a substance and classification of
ADR (Adverse Drug Reaction).
Presented at the conference were: the adverse event
database of the WHO, the Yellow Card System of the
British MHRA, systems established by the BfArM, the
EMA, the ESCOP, the Italian Herb Surveillance
Programme of National Institute of Health, the
German producers of anthroposophic medicines, the
Australian Adverse Drug Reactions Unit, the system
installed by the Chinese drug regulatory authorities,
although actually still in Chinese language, demonstrating
that the emerging problem has been the lack of
communication among the systems.
In contrast with the wide traditional use of medicinal
herb, there is a lack of reliable scientific data and
notwithstanding long tradition there is further confusion
since some products can be commercialized for uses
completely different from the original traditional use and
vice versa.
As Dr Phil Routledge, Wales College of Medicine,
outlined strategies for risk management of herbal medi-
cines stressing the need to be based on the following
main steps: clear-cut identification, reliable assessment,
management and clear communication to the public.
The assessment of risk should be primarily based on the
following points: hazard identification and complete
estimation of risk.
Dr Shufeng Zou of the National University of
Singapore focused attention on the problems of predict-
ing and minimizing herb–drug interactions by expanding
knowledge not only of substances contained in the
extract but also by improving the quality of the
commercial product through controls on the manufac-
turer, packer and distributor.
Dr Ralph Edwards reported the global experience of
the WHO Drug Monitoring Programme. On April 2006,
a total number of 3.6 million of ADR were reported and
of these, 41439 have been listed as due to an herbal drug
and 17112 of these as due to interaction with another
drug. In the last 12 years, the number of suspected herbal
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properly cited.ADRs has more than tripled. He stressed the lack of an
internationally standardized classification that has led to
the publication of the Accepted Scientific Names of
Therapeutic Plants and their Synonyms by the WHO and
proposed the creation of an Herbal Code Number.
Dr Ulrich Hagemann, of the German Federal Institute
for Medical Devices, proposed that one of the main
concerns is to develop not only an affordable inter-
nationally acknowledged system for herb classification
but also to classify substances contained in extracts,
based on affordable studies of pharmakokinetic and
pharmacodynamic parameters of main herbal compo-
nents, dosage and real exposure as well as possible ADR
versus underlying disease.
Dr Ano Dodoo of Ghana National Centre for
Pharmacovigilance described work in Africa to diffuse a
program about herbal pharmacovigilance, and to identify
products and herbal constituents for full assessment of
adverse reaction with the same priorities as Western
countries.
The Association of British Pharmaceutical Industry
reported a study showing that 60% of people using
herbal remedies took them along with conventional
medicines and only 10% of the patients taking alternative
medicines informed their GPs, stressing the importance of
education of both the prescriber and the patient.
The most important medicinal herbal ADR
reports centered on Hypericum perforatum, kava-kava,
pyrrolizidine alkaloid and aristolochic acid. Although
these have been the most studied and paradigmatic cases,
other problems are pending due to the under-reporting of
herbal ADR. Dr Linda Anderson of the Medicines and
Healthcare Products Regulatory Agency, UK, stressed
that remedies are often made by simple processes with no
brand name on the merchandized product and neither
written recommendation nor warnings.
Many authors have remarked on the importance of
contaminants like pesticides, heavy metals and mycotox-
ins, and Dr Patricia McElhatton, National Teratology
Information Service, UK, in her work reported a lack of
rigorous scientific studies on the safety of herbs for
pregnant or lactating mothers in contrast with the
widespread use of herbal medicines in this group of
women.
The implementation of the Directive 2004/24/EC on
Traditional Herbal Medicinal Products has introduced a
registration scheme which requires traditional herbal
medicines to meet specific and appropriate standards of
safety and quality, and for the product to be accom-
panied by the necessary information for safe use.
In addition, the 2001 Review of Medicines Legislation
has provided a number of new regulatory tolls such as
electronic reporting of adverse reactions to the central
European database: Eudravigilance.
Dr Tony Booker, Register of Chinese Herbal Medicine,
UK, presented data of a study from Mazin Al-Kafai (not
published) showing that on a total of 1265 patients
taking Chinese herbs for different diseases, 107 patients
(8.5%) developed raised levels of ALT after initially
having normal results. He pointed out the importance of
improving the dissemination of reports among practi-
tioners at all levels.
Dr Simon Mills, an ESCOP (European Scientific
Cooperative of Phytotherapy) representative, confirmed
the involvement of the institution in pharmacovigilance
through publication of a monograph that provides the
basis for a formal European harmonized ‘core data’
sheet. The mission of the EU BIOMED research program
is to determine European standards for the safe and
effective use of phytomedicines.
According to Dr Stephan Kohler, representative of
pharmaceutical industries, the scope of pharmaceutical
EU legislation should be not only to plan and control
pharmacovigilance and to protect public health but also
to increase the competitiveness of the industry and
facilitate the development of new products and the
movement of safe goods in the community.
Participants approved the principle that pre-clinical
tests for a medicinal product may not be necessary when
its traditional use has not been harmful under specified
conditions during a period of at least 30 years, including
at least 15 in the community.
Dr Joanne Barnes, the Congress Chairperson, outlined
the importance of the pharmacists’ role in controlling
ADRs, and also in correctly informing patients on the
risk and benefits of herbal medicines.
The best poster award was presented by Dr Paola
Moro, Milan Poison Control Centre, I, for reporting
details of the 1378 calls they had received concerning
alternative remedies since January 2001. The presenters
remarked on the difficulties in quickly identifying toxic
substances and alerting authorities to take urgent action
to protect public health.
In conclusion, the main problems concerning herbal
ADRs are botanical and chemical identification of the
substances taken by patients, correct evaluation of ADRs
following the principles of mainstream medicine and
education of practitioners, citizens who commonly think
herbs are always safe, producers and merchandizers.
The next step will be to build an international
cooperative affordable network for pointing out and
evaluating herbal ADRs.
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